These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7300086)

  • 1. [Slow trasicor in the treatment of essential hypertension].
    Giec L; Sledziński Z; Trusz-Gluza M; Nieszporek T; Hübner D; Mleczko Z; Olwiński M
    Kardiol Pol; 1981; 24(9):625-30. PubMed ID: 7300086
    [No Abstract]   [Full Text] [Related]  

  • 2. Slow-Trasicor (sustained-release oxprenolol hydrochloride 160 mg) in the treatment of essential hypertension: a multicentre evaluation of 4,400 patients.
    Forrest WA
    Br J Clin Pract; 1977 Nov; 31(11):181-6. PubMed ID: 339937
    [No Abstract]   [Full Text] [Related]  

  • 3. [Evaluation of the hypotensive effect of slow-release Trasicor].
    Cybulska I; Brym E
    Kardiol Pol; 1982; 25(4):329-35. PubMed ID: 6755030
    [No Abstract]   [Full Text] [Related]  

  • 4. A comparison of slow Trasicor (oxprenolol 160 mg) and Trasidrex (oxprenolol 160 mg and cyclopenthiazide 0.25 mg) in the treatment of hypertension in general practice.
    Elsdon-Dew RW; Holden E
    J Int Med Res; 1981; 9(5):315-8. PubMed ID: 7028531
    [No Abstract]   [Full Text] [Related]  

  • 5. One year efficacy and tolerability of oxprenolol slow-release and chlorthalidone on fixed combination in mild to moderate hypertension.
    Masoni A; Tomasi AM; Pirani R; Lazzaretto R; Ambroso G
    G Ital Cardiol; 1981; 11(12):2105-9. PubMed ID: 7346306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trasidrex (a fixed combination of slow Trasicor 16o mg and Navidrex 0.25mg) in the treatment of hypertension: a multicentre clinical trial in general practice.
    Ebbut AF; Elsdon-Dew RW; Murphy JE
    J Int Med Res; 1978; 6(6):494-8. PubMed ID: 720740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oxprenolol in the treatment of essential arterial hypertension].
    Soto Rojas G
    Prensa Med Mex; 1976; 41(5-6):188-93. PubMed ID: 792867
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of oxprenolol plus chlorthalidone in fixed combination against chlorthalidone alone in mild to moderate essential hypertension; a clinical trial.
    Gruppillo P; Tomasi AM; Masoni A; Finzi C
    G Ital Cardiol; 1980; 10(4):476-9. PubMed ID: 7002694
    [No Abstract]   [Full Text] [Related]  

  • 9. A multicentre study examining the substitution of Trasidrex for the free combination of Slow-Trasicor and Navidrex-K.
    Ebbutt AF; Elsdon-Dew RW
    J Int Med Res; 1979; 7(6):524-7. PubMed ID: 520655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Test with the use of the adrenergic beta receptor blockader trasicor in the differential diagnosis of arterial hypertension].
    Velikanov KA; Shvets VD
    Sov Med; 1983; (4):88-91. PubMed ID: 6135258
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hypotensive effect of delayed-action oxprenolol and chlorthalidone in combined form in patients with primary arterial hypertension].
    Cybulska I; Sznajderman M
    Pol Tyg Lek; 1984 Apr; 39(15):501-3. PubMed ID: 6384962
    [No Abstract]   [Full Text] [Related]  

  • 12. Once daily slow-release hydralazine in hypertension.
    O'Boyle CP; Kelly J; O'Brien ET; O'Malley K
    Ir Med J; 1981 Apr; 74(4):115-6. PubMed ID: 7228629
    [No Abstract]   [Full Text] [Related]  

  • 13. A fixed combination of oxprenolol slow-release and chlorthalidone once daily in treatment of mild to moderate hypertension.
    Muiesan G; Agabiti-Rosei E; Buoninconti R; Carotti A; Fariello R; Innocenti P; Toso M; Valori C; Motolese M
    Int J Clin Pharmacol Ther Toxicol; 1981 Jun; 19(6):249-55. PubMed ID: 7309298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Slow-release oxprenolol and chlortalidone administered once daily in essential hypertension].
    Rossi A; Ziacchi V; Fracalossi C; Marino A; Lomanto B
    Minerva Cardioangiol; 1984 Dec; 32(12):949-62. PubMed ID: 6531101
    [No Abstract]   [Full Text] [Related]  

  • 15. [Use of oxprenolol, triamterene, and dihydralazine in the treatment of essential hypertension].
    Gerc V; Numić N
    Med Arh; 1980; 34(1):51-9. PubMed ID: 7007752
    [No Abstract]   [Full Text] [Related]  

  • 16. [Slow-release hydralazine in the treatment of essential arterial hypertension].
    Moscovici H; Yasbeck Júnior P; Fadul Neto J
    Arq Bras Cardiol; 1982 Sep; 39(3):197-9. PubMed ID: 7186366
    [No Abstract]   [Full Text] [Related]  

  • 17. Experience with sustained-release oxprenolol (slow trasicor) in the management of hypertension in general practice.
    Forrest WA
    J Int Med Res; 1979; 7(4):318-23. PubMed ID: 488521
    [No Abstract]   [Full Text] [Related]  

  • 18. [Multicenter study with a fixed combination of oxprenolol/chlorthalidone in essential arterial hypertension].
    Albanesi Filho FM; Benchimol AB
    Arq Bras Cardiol; 1980 May; 34(5):409-14. PubMed ID: 7006573
    [No Abstract]   [Full Text] [Related]  

  • 19. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
    Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experience in the ambulatory treatment of primary arterial hypertension with a fixed oxprenolol-chlorthalidone combination].
    Zampaglione G; Ferrari O; Bianchi C; Bonifazi C; Coppetti S; Costanza G; Lanzarini L; Ricevuti A; Rinaldo R; Rizzi GM; Tavecchi L; Ziletti G; Distante S
    G Clin Med; 1980 Oct; 61(10):776-88. PubMed ID: 7239053
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.